Condition

Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

ClinicalTrials.gov condition label

Clinical trials1

Recruiting0

Common interventions1

Lead sponsors shown1

Clinical trials

1 shown

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 PositiveNCT03178071

NO_LONGER_AVAILABLE

Common interventions

LorlatinibDRUG1

Leading sponsors

Pfizer1

Trial status mix

NO_LONGER_AVAILABLE1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.